FINWIRES · TerminalLIVE
FINWIRES

ASX:AVH

5 stories mentioning ASX:AVHUpdated 36m ago

Every FINWIRES story that references ASX:AVH, newest first.

Asia

Avita Medical Reports Encouraging UK Evaluation of Wound Care System

Avita Medical (ASX:AVH) said its Recell GO wound care system was successfully evaluated in the UK, with investigators reporting healing and complete graft take across a range of burn and reconstructive procedures, according to a late Thursday statement.The medical system prepares a patient's own skin cells into a liquid that can be sprayed directly onto wounds to promote healing.Recell data presented during the British Burn Association's annual meeting also pointed to workflow benefits, including reduced procedural variability, improved consistency of cell preparation, and enhanced operating room efficiency, the company said.

ASX:AVH
Asia

Avita Medical Posts Narrower Q1 Loss, Higher Revenue; Reaffirms Full-Year 2026 Outlook

Avita Medical (ASX:AVH) reported Friday a March quarter net loss of $0.35 per share, compared with $0.53 a year earlier.Revenue for the three months ended March 31 was $19.3 million, compared with $18.5 million a year earlier.The company reaffirmed its full-year guidance, with revenue expected in the range of $80 million to $85 million.Its shares rose 1% in recent trading on Friday.

ASX:AVH
Asia

Avita Medical Appoints CEO, Chair

Avita Medical (ASX:AVH) has appointed Cary Vance as chief executive, effective immediately, according to a Friday Australian bourse filing.Vance has been acting as interim CEO since October 2025, per the filing.The company also appointed Jan Stern Reed as chair with immediate effect, the filing added.

ASX:AVH
Asia

Avita Medical Says Wound Care System Preparation Method Receives Regulatory Approval in Australia, New Zealand

Avita Medical (ASX:AVH) said its RECELL GO wound care system preparation method received regulatory clearance in Australia and New Zealand, allowing for commercialization in both markets for burn and acute wound treatment, according to a Thursday Australian bourse filing.It secured certification from Australia's Therapeutic Goods Administration and was listed on New Zealand's Web Assisted Notification of Devices database by Medsafe.RECELL GO combines a reusable, electricity-powered RECELL processing device with a single-use RECELL preparation kit, with one such kit capable of treating wounds up to 1,920 square centimeters, per the filing.Its exclusive distribution partner in Australia and New Zealand, Revolution Surgical, expects to begin the commercial launch within the coming weeks.Its shares rose over 2% in recent trading on Thursday.

ASX:AVH
Asia

Avita Medical Reports Positive Interim Results From Cohealyx-I Wound Care Study

Avita Medical (ASX:AVH) said interim results from its Cohealyx-I multi-center study showed a reduction of nearly 20 days in the mean time to skin grafting, at 13.6 days compared with a 33.2-day real-world benchmark, for patients with full-thickness wounds, according to a Wednesday Australian bourse filing.The study's primary endpoint is time to autografting, and the secondary endpoints include wound healing and safety outcomes, per the filing.The company said the interim analysis of 40 patients showed a median time to grafting of 11 days, with grafting achieved as early as five days, 25% of patients grafted within seven days, and 72% grafted within 14 days.The study is ongoing, with the full dataset expected this year.

ASX:AVH

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:AVH in your portfolio
WheelAI
WheelAI
Analyze ASX:AVH options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:AVH